ADA on OTC oral health care
This article was originally published in The Rose Sheet
Executive Summary
When an antiplaque claim is made for an OTC oral healthcare product, that product "should also be required to show that it is effective in reducing gingivitis," the American Dental Association asserts in comments to FDA Nov. 25. ADA supports FDA's recommendations in its advance notice of proposed rulemaking, but runs counter to industry's suggestion that antiplaque claims should stand on their own (1"The Rose Sheet" Dec. 1, 2003, p. 3). ADA also says it is "rational" to combine an anticaries or desensitizing agent with a Category I antigingivitis/antiplaque agent. However, supporting data "should be submitted demonstrating that specific combination products are safe and effective for all indications," trade group adds. ADA further points out that while chlorhexidine digluconate has not been marketed for a material time and to a material extent for OTC use in the U.S., it has been used in prescription products with significant published data supporting its safety and efficacy...
You may also be interested in...
Combination Oral Health Care Product Safety Defended By Industry
Combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.